|

Statins Study in Children of Acute Kawasaki Disease With Coronary Artery Abnormalities

RECRUITINGPhase 3Sponsored by Children's Hospital of Fudan University
Actively Recruiting
PhasePhase 3
SponsorChildren's Hospital of Fudan University
Started2026-06-08
Est. completion2027-08-31
Eligibility
Age2 Years – 18 Years
Healthy vol.Accepted

Summary

The goal of this observational study is to learn about the safety and effects of atorvastatin in treatment of Chinese Kawasaki disease (KD) children complicated with coronary artery abnormalities (CAA) in acute phase. The main questions it aims to answer are: Is atorvastatin safe in Chinese children of acute KD? Does atorvastatin contribute to control the acute inflammation in KD and improve the CAA?

Eligibility

Age: 2 Years – 18 YearsHealthy volunteers accepted
Inclusion Criteria:

* KD complicated with CAA, less than 20 days after the onset of KD, or more than 20 days after onset but the KD inflammation has not been controled.
* IVIG and/or other anti-inflammatory treatments have been used/are being used.
* The guardians agree to atorvastatin treatment and sign the informed consent form.

Exclusion Criteria:

* Patients with history of family hypercholesterolemia/taking statins/severe chronic diseases.
* Patients with abnormal laboratory data including CK≥500U/L, total cholesterol\<3.1mmol/L, ALT or AST≥ 2 times the upper limit of normal.
* The guardians do not agree to atorvastatin treatment.

Conditions3

Coronary Artery AbnormalitiesHeart DiseaseKawasaki Disease

Interventions3

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.